Be the first to like.

Share

Real progress is being made using CRISPR and related gene-editing techniques to alter cells taken from people with diseases such as sickle cell and genetic forms of blindness. These approaches are likely to offer safer and more reliable ways of making changes to a person at the genetic level. What makes these uses much less ethically challenging [than germline editing] is that they only affect the person being treated; the genetic modifications can’t be passed on to future generations.

Jeffrey Kahn, PhD, MPH ’88, is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics.

…continue reading ‘Should CRISPR Be Used to Edit Human Genes to Treat Genetic Diseases?’

Be the first to like.

Share
Hopkins Bloomberg Public Health Magazine

Tags: , , , , , , , , , , ,

Leave a Reply